Comerica Bank
MAZE

Comerica Bank’s Maze Therapeutics MAZE Stock Holding History

Comerica Bank’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-636
Closed -$7K – 3814
2025
Q1 		$7K Buy
+636
New +$7.66K ﹤0.01% 3256

Other funds holding MAZE

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Comerica Bank's MAZE Position: Q2 2025 in Review

Comerica Bank sold out of Maze Therapeutics (MAZE) in Q2 2025, closing a stake of 636 shares — an estimated $7K sold.

Comerica Bank first reported a position in MAZE in Q1 2025 and held it in 1 quarter. The position peaked at $7K in Q1 2025. 75 funds tracked by Wall St. Rank hold MAZE as of Q2 2025.

  • Comerica Bank reported no remaining Maze Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Comerica Bank sold 636 Maze Therapeutics shares in Q2 2025, an estimated $7K.
  • Comerica Bank first reported a position in Maze Therapeutics in Q1 2025 and held it in 1 quarter.
  • Comerica Bank's Maze Therapeutics position peaked at $7K in Q1 2025.
  • 75 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2025.

Based on Comerica Bank's 13F filing for Q2 2025, filed 14 Aug 2025.